The IL-13R alpha2 paves the way for anti-glioma nanotherapy

Авторы: Ulasov Ilya V., Borovjagin Anton, Laevskaya Anastasia, Kamynina Margarita, Timashev Peter, Cerchia Laura, Rozhkova Elena A.
Журнал: Genes & Diseases
Год издания: 2021
DOI: 10.1016/j.gendis.2021.08.006
Аннотация: Glioblastoma (GBM) is one of the most aggressive (grade IV) gliomas characterized by a high rate of recurrence, resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients’ survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnostics and management of brain cancers. In the current review, we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover, we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor targeting in GBM early diagnostics and experimental therapy.
Добавил в систему: Тимашев Петр Сергеевич

№	Имя	Описание	Имя файла	Размер	Добавлен
1.	1-s2.0-S2352304221001033-main.pdf		1-s2.0-S2352304221001033-main.pdf	1,7 МБ	28 сентября 2021 [TPS_SU]

	ИСТИНА	Войти в систему Регистрация
	ИПМех РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА